Faron Pharmaceuticals Oy Share Discussion Threads

[hashertu] 30/12/2019 15:40

this1. Thanks. I missed that RNS because it was RNS Reach.

[this1] 30/12/2019 11:58

IMO Faron can only gain with this arbitration. If Rentchler has breached the contract Faron might be getting huge compensations since phase III in Europe and Japan was done with Rentchler drug substance.Now if Faron cannot use anymore Rentchlers drug substance, they probably need to do additional clinical testing with the other manufacturer's drug substance. Rentchler is in risk of beeing the one who pays the bill of new phase III or whatever new testing is required.Third party is covering the costs of the arbitration on behalf of Faron. This is probably a law firm and they need to be quite sure of winning the case when they are willing to risk this kind of money if they would lose the case.All IMO of course. DYOR.Anyway Faron already has a second manufacturing site for Traumakine: https://www.faron.com/news-events/news-and-press-releases?rnsid=974158&cid=2223

[hashertu] 30/12/2019 10:26

This arbitration is an interesting twist.

[this1] 27/12/2019 13:07

Interesting video from Faron's webpages:https://drive.google.com/file/d/1bMKyc1gSY6wYBTs1ABN998ZI2_bvrD9t/view

[costax1654x] 27/12/2019 11:20

Idp looks ready for a rally

[bwgs] 23/12/2019 15:21

Still staying in the 270+ range

[latifs100] 12/12/2019 15:19

yes from 80p to now

[daffodil4] 12/12/2019 14:59

I think this was always going to retrace back
to the placing price £1.90. Looks like FDA
update on T will be next year..could be
a sell off as a lot sitting on very good profit
and risk it if the T update is not positive!
GLA!

[costax1654x] 11/12/2019 09:59

Circassia looks interesting with two drugs approved already by FDA,mcap 80 mil

[this1] 11/12/2019 08:21

Seems Faron's people have a presentation at Esmo also today 11.12 additionally to 13.12:New tools to prevent cancer growth and spread: A clever approachLecture Time11:20 - 11:40SpeakersM. Hollmén (Turku, Finland)AuthorsM. Hollmén (Turku, Finland)http://194.6.170.42/slidecenter/immuno2019/attendee/confcal/session/calendar/2019-12-11

[milliecusto] 11/12/2019 08:00

Good news, but long journey ahead, will spike then fall back

[amrishbhim] 09/12/2019 08:36

Check out dmtr RNS

[toffeeman] 07/12/2019 20:47

5 minutes to present!!

[this1] 07/12/2019 08:37

Faron will be at Esmo's Immuno-Oncology Congress on 13.12, Geneve:Mini Oral session 2Date13.12.2019Lecture Time08:00 - 08:00Mini Oral session2O - Biomarkers of immune switch induced by a novel anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) in MATINS trial patients with advanced solid tumoursPresentation Number2OLecture Time08:00 - 08:05SpeakersM. Hollmén (Turku, Finland)AuthorsM. Hollmén (Turku, Finland) R. Virtakoivu (Turku, Finland) P. Jaakkola (Helsinki, Finland) A. Minchom (London, United Kingdom) S. Jalkanen (Turku, Finland) M. Karvonen (Turku, Finland) J. Mandelin (Turku, Finland) J. Koivunen (Oulu, Switzerland) P. Bono (Helsinki, Finland)AbstractBackgroundA scavenger receptor CLEVER-1 is highly expressed on tumor associated macrophages (TAMs) and mediates the clearance of "unwanted" self-components. Pre-clinical studies demonstrate that CLEVER-1 inhibition increases TAM pro-inflammatory cytokine secretion and antigen presentation reactivating CD8+ T cell responses with robust anti-tumor activity (Viitala et al., 2019). Targeting CLEVER-1 could overcome the immunosuppressive tumor microenvironment and has led to the development of FP-1305, a humanized anti-CLEVER-1 IgG4-antibody.MethodsMATINS (Macrophage Antibody To INhibit immune Suppression) trial is a multicenter first-in-human phase I/II study (NCT03733990) to assess the tolerability, safety and preliminary efficacy of FP-1305 in patients with advanced, IO-refractory melanoma, cholangiocarcinoma, hepatocellular, colorectal, and pancreatic ductal adenocarcinoma. Biomarker analysis included CLEVER-1 determination, immune cell profiling by mass cytometry and analysis of cytokine production.Results11 patients (median age 57) were enrolled in four cohorts (0.3, 1.0, 3.0 or 10?mg/kg) and received 1-8 cycles (median 3) of FP-1305 every three weeks. FP-1305 has been well tolerated without dose-limiting toxicities and maximum tolerated dose (MTD) has not been reached. Promising early efficacy results have recently been reported (ESMO 2019, LBA19). FP-1305 dosing led to increased Th1 skewing (CXCR3+CCR6-) of CD4 and CD8 T cell populations with downregulation of several inhibitory immune checkpoint molecules. Increase in circulating IFN gamma was detected but it was most prominent in the patient showing durable partial response.ConclusionFP-1305 is the first macrophage checkpoint inhibitor candidate promoting immune switch with promising tolerability and clinical anti-tumor activity. FP-1305 represents a novel treatment option to provoke immune response against cold tumors.Clinical trial identificationNCT03733990.Legal entity responsible for the studyFaron Pharmaceuticals.

[milliecusto] 04/12/2019 16:53

Sln looking very good aswell

[daffodil4] 03/12/2019 10:56

I think the placement shares are being sold
under the radar as no holder took over the
reporting threshold....50% profit....
I think it will struggle to stay at this level...
Big thing now is news on T does it get go ahead
for another phase 3.....who will pay if it does??
What would happen to share price if it does not?
Should know this month...

[bwgs] 03/12/2019 09:36

I'd go for sooner than later, see these going 300 + today. MMs had their fun this morning

[latifs100] 03/12/2019 08:50

need balls to hold on to this share. what price ppl getting in again at

[this1] 03/12/2019 08:47

Yes, it is. The current price in First North is around 340 gbx

[milliecusto] 03/12/2019 08:37

All games to hunt for shares

[inv] 02/12/2019 18:35

getting there

[inv] 29/11/2019 08:19

with a nasdaq listing this will hit £3.50 plus

[uk2day] 29/11/2019 08:17

Go and crawl back under your rock costax no one want to buy your pump n dump stock CIR!!!

[costax1654x] 28/11/2019 15:38

Have a look

[costax1654x] 28/11/2019 15:37

CIR,Circassia next one to go big time